RxDoctor Payments Data

Kelly O Callahan, MD

Gastroenterology · Worcester, MANPI 1427056795

Payments from drug & device makers

$6,381in general payments, 2019–2025

Across 305 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$405
  • Takeda Pharmaceuticals U.S.A., Inc.$299
  • Pfizer$250
  • Ferring Pharmaceuticals Inc.$239
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$6,34699%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,381 in reported general payments places this provider in the 70th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$87,114
Medicare patients
467
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$175,385
LinzessLinaclotide120$104,378
Mesalamine37$25,629
Dexlansoprazole DrDexlansoprazole40$19,355
PentasaMesalamine12$17,206
MotegrityPrucalopride Succinate19$11,957
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates113$6,504
Pantoprazole Sodium264$5,558
Budesonide EcBudesonide20$4,908
Colestipol Hcl34$4,331
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$4,173
Famotidine298$3,447
Omeprazole225$3,190
Balsalazide Disodium13$2,886
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl171$2,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,642$104,378120 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$299$11,95719 claims
Ferring Pharmaceuticals Inc.Clenpiq$239$4,17324 claims
Braintree Laboratories, Inc.Sutab$128$1,95612 claims
SandozLansoprazole$97$89342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →